Pfizer (PFE) Cash & Current Investments (2009 - 2026)

Pfizer (PFE) has 18 years of Cash & Current Investments data on file, last reported at $13.1 billion in Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $13.1 billion, down 24.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.1 billion (down 24.5% YoY), and the FY2025 annual result was $13.6 billion, down 33.6% from the prior year.
• Cash & Current Investments slipped to $13.1 billion in Q1 2026 per PFE's latest filing, from $13.6 billion in the prior quarter.
• Over five years, Cash & Current Investments peaked at $44.8 billion in Q3 2023 and troughed at $7.1 billion in Q2 2024.
• A 5-year average of $21.1 billion and a median of $17.3 billion in 2025 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2024 and 2025: Cash & Current Investments slumped 84.15% in 2024, then surged 86.61% in 2025.
• A 5-year view of Cash & Current Investments shows it stood at $22.7 billion in 2022, then sank by 44.18% to $12.7 billion in 2023, then surged by 61.36% to $20.5 billion in 2024, then tumbled by 33.6% to $13.6 billion in 2025, then retreated by 3.83% to $13.1 billion in 2026.
• Business Quant data shows PFE's Cash & Current Investments at $13.1 billion in Q1 2026, $13.6 billion in Q4 2025, and $15.0 billion in Q3 2025.